Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

ESGCT preclinical roundup; plus Generation, Pionyr and more

BioCentury’s roundup of translational news

October 23, 2021 12:52 AM UTC

Preclinical data from companies presenting at the European Society of Gene and Cell Therapy (ESGCT) 2021 Virtual Congress highlight a range of gene editing strategies and delivery modalities nearing the clinic.

Beam Therapeutics Inc. (NASDAQ:BEAM) showed its lipid nanoparticle (LNP)-delivered base editing therapy corrected R83C in G6PC, one of the primary disease-causing mutations of glycogen storage disorder 1a, and prevented growth impairment and metabolic defects in diseased mice...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article